Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011:7:495-9.
doi: 10.2147/NDT.S23721. Epub 2011 Aug 24.

Minimally invasive biomarker confirms glial activation present in Alzheimer's disease: a preliminary study

Affiliations

Minimally invasive biomarker confirms glial activation present in Alzheimer's disease: a preliminary study

Napapon Sailasuta et al. Neuropsychiatr Dis Treat. 2011.

Erratum in

  • Erratum: corrigendum.
    [No authors listed] [No authors listed] Neuropsychiatr Dis Treat. 2011;7:707. doi: 10.2147/NDT.S28295. Epub 2011 Nov 25. Neuropsychiatr Dis Treat. 2011. PMID: 22247611 Free PMC article.

Abstract

We applied (13)C magnetic resonance spectroscopy (MRS), a nonradioactive, noninvasive brain imaging technique, to quantify the oxidation of [1-(13)C] acetate in a conventional clinical magnetic resonance imaging (MRI) scanner in five consecutive elderly subjects at various clinical stages of Alzheimer's disease (AD) progression. [1-(13)C] acetate entered the brain and was metabolized to [5-(13)C] glutamate and glutamine, as well as [1-(13)C] glutamate and glutamine, and the final glial oxidation product, (13)C bicarbonate, at a linear rate. Calculation of the initial slope was similar in a single subject, examined twice, 1 month apart (test-re-test 8%). Mean rate of cerebral bicarbonate production in this elderly group was 0.040 ± 0.01 (n = 5). Assuming that the rate of conversion of acetate to bicarbonate is a reflection of glial metabolic rate and that glial metabolic rate is a surrogate marker for 'neuroinflammation', our preliminary results suggest that [1-(13)C] MRS may provide biomarkers for diseases, believed to involve microglia and other cells of the astrocyte series. Among these is AD, for which novel drugs which ameliorate the damaging effects of neuroinflammation before symptoms of dementia appear, are in advanced development. The value of (13)C MRS as an early, noninvasive biomarker may lie in the conduct of cost-effective clinical trials.

Keywords: Alzheimer’s disease; glial activation; noninvasive biomarker.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Proton MRS spectra from healthy elderly (A), an elderly subject with MCI (B) and an AD patient (C). Spectra were scaled to creatine peak intensity. Abbreviations: AD, Alzheimer’s disease; MCI, mild cognitive impairment; mI, myo-inositol; MRS, magnetic resonance spectroscopy; NAA, N-acetyl aspartate.
Figure 2
Figure 2
Typical spectra (147–167 ppm region) of 13C MRS in an AD subject at baseline (A) and at 1 hour after start of infusion (B). Abbreviations: MRS, magnetic resonance spectroscopy; AD, Alzheimer’s disease; tCr, total creatine.
Figure 3
Figure 3
Significant correlation of the rate of bicarbonate productions in % fractional enrichment (FE) of bicarbonate per minute and the clinical measure, mini-mental state examination (MMSE) with R2 = 0.908 (A) and glial cell density from proton MRS (mI/Cr) with R2 = 0.753 (B). Abbreviations: AD, Alzheimer’s disease; Cr, creatine; FE, fractional enrichment; mI, myo-inositol; MCI, mild cognitive impairment; MRS, magnetic resonance spectroscopy; MMSE, mini-mental state examination.

Similar articles

Cited by

References

    1. Kim S, Swaminathan S, Shen L, et al. Genome-wide association study of CSF biomarkers Abeta 1–42 t-tau, and p-tau181p in the ADNI cohort. Neurology. 2011;76(1):69–79. - PMC - PubMed
    1. Shaw LM, Vanderstichele H, Knapik-Czajka M, et al. Qualification of the analytical and clinical performance of CSF biomarker analyses in ADNI. Acta Neuropathol. 2011;121(5):597–609. - PMC - PubMed
    1. Krause DL, Muller N. Neuroinflammation, microglia and implications for anti-inflammatory treatment in Alzheimer’s disease. Int J Alzheimers Dis. 2010;2010:732806. - PMC - PubMed
    1. Jack CR, Jr, Knopman DS, Jagust WJ, et al. Hypothetical model of dynamic biomarkers of the Alzheimer’s pathological cascade. Lancet Neurol. 2010;9(1):119–128. - PMC - PubMed
    1. Godbolt AK, Waldman AD, MacManus DG, et al. MRS shows abnormalities before symptoms in familial Alzheimer disease. Neurology. 2006;66(5):718–722. - PubMed